financetom
Market
financetom
/
Market
/
Why Nutanix Stock Is Trading Higher Monday
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Why Nutanix Stock Is Trading Higher Monday
Sep 8, 2025 1:38 PM

Nutanix Inc ( NTNX ) shares are trading higher Monday afternoon following a Friday announcement from S&P Global that the cloud computing company will be added to the S&P MidCap 400 index.

The change is set to take effect prior to the opening of trading on Monday, Sept. 22.

Check the market position of NTNX here.

The inclusion of Nutanix ( NTNX ) in the widely followed index is a significant milestone for the company. Index inclusion typically leads to increased demand for a company’s shares from index funds and other institutional investors that track the S&P MidCap 400. Nutanix ( NTNX ) will replace Acadia Healthcare Company Inc ( ACHC ) in the index.

Benzinga Edge Rankings: Benzinga Edge stock rankings give you four critical scores to help you identify the strongest and weakest stocks to buy and sell. Based on this data, while Nutanix ( NTNX ) shows a solid Growth score of 57.77, it has a very low Value score of 8.29.

NTNX Price Action: According to data from Benzinga Pro, Nutanix ( NTNX ) shares are trading higher by 7.24% to $74.98 on Monday afternoon. The stock has a 52-week high of $83.36 and a 52-week low of $54.66.

How To Buy NTNX Stock

Besides going to a brokerage platform to purchase a share — or fractional share — of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument.

For example, in Nutanix’s case, it is in the Information Technology sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.

Read Also:

Summit Therapeutics’ Lung Cancer Drug Under Dark Clouds As Keytruda Challenger Shows Regional Data Differences

Image: Shutterstock

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Copyright 2023-2026 - www.financetom.com All Rights Reserved